Weingarten Jeremy A, Bellner Lars, Peterson Stephen J, Zaw Moe, Chadha Puja, Singh Shailendra P, Abraham Nader G
.
Horm Mol Biol Clin Investig. 2017 Sep 1;31(2):/j/hmbci.2017.31.issue-2/hmbci-2017-0029/hmbci-2017-0029.xml. doi: 10.1515/hmbci-2017-0029.
Obstructive sleep apnea (OSA) has a strong association with cardiovascular and metabolic abnormalities, although the mechanism driving this association is not well established. NOV/CCN3, a multifunctional extracellular matrix protein, may play a mechanistic and/or prognostic role in these associations. We hypothesized that patients with OSA, which primarily affects obese individuals, will have increased levels of NOV, and that NOV can serve as a biomarker in patients to predict OSA as well as metabolic and cardiac risk. Ten morbidly obese and 10 healthy lean subjects underwent overnight polysomnography (PSG) and clinical evaluation. Blood samples were analyzed for NOV levels, adiponectin and IL-6. OSA was found in nine obese subjects and three lean subjects. NOV levels were significantly higher in the OSA vs. no OSA group (2.1 ± 0.9 vs. 1.3 ± 0.8, p < 0.03). NOV levels were significantly higher in the obese vs. lean group (2.2 ± 0.3 vs. 1.4 ± 0.2-fold change, p < 0.03). Among lean subjects, NOV levels were significantly higher in the OSA vs. no OSA group (2.1 ± 0.9 vs. 1.0 ± 0.4, p < 0.05). NOV and AHI were positively correlated (ρ = 0.49, p = 0.033). IL-6 and adiponectin differences in obese vs. lean and OSA vs. no OSA were consistent with an inflammatory phenotype in obese subjects and OSA subjects. NOV is a novel biomarker of the presence and severity of OSA and a potential marker of future cardiovascular and metabolic disease in OSA patients.
阻塞性睡眠呼吸暂停（OSA）与心血管和代谢异常密切相关，尽管这种关联背后的机制尚未完全明确。NOV/CCN3是一种多功能细胞外基质蛋白，可能在这些关联中发挥机制性和/或预后作用。我们推测，主要影响肥胖个体的OSA患者的NOV水平会升高，并且NOV可作为预测患者OSA以及代谢和心脏风险的生物标志物。10名病态肥胖受试者和10名健康瘦受试者接受了整夜多导睡眠图（PSG）检查和临床评估。对血样进行了NOV水平、脂联素和白细胞介素-6的分析。在9名肥胖受试者和3名瘦受试者中发现了OSA。OSA组的NOV水平显著高于无OSA组（2.1±0.9对1.3±0.8，p<0.03）。肥胖组的NOV水平显著高于瘦组（2.2±0.3对1.4±0.2倍变化，p<0.03）。在瘦受试者中，OSA组的NOV水平显著高于无OSA组（2.1±0.9对1.0±0.4，p<0.05）。NOV与呼吸暂停低通气指数（AHI）呈正相关（ρ=0.49，p=0.033）。肥胖与瘦以及OSA与无OSA之间的白细胞介素-6和脂联素差异与肥胖受试者和OSA受试者的炎症表型一致。NOV是OSA存在和严重程度的新型生物标志物，也是OSA患者未来心血管和代谢疾病的潜在标志物。
